Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) An aqueous formulation of a therapeutic agent comprising:

rapamycin in a pharmaceutically effective dosage;
ethanol in a residual concentration of about 1.57 percent by weight;
vitamin E TPGS in an amount of about 6.55 percent by weight; and
water in an amount of about 90.51 percent by weight, the rapamycin,
vitamin E TPGS and water forming a stable aqueous solution, thereby
remaining a solution without precipitation, the stable aqueous formulation
comprising a final solution of rapamycin in the range from about 4 mg/ml to
about 15 mg/ml.

- 2. (Cancelled)
- 3. (Cancelled)
- 4. (Currently Amended) The <u>liquid aqueous</u> formulation according to claim <u>1</u> 3, wherein the rapamycin <u>comprises</u> <u>is</u> sirolimus.
- 5. (Currently Amended) The <u>liquid aqueous</u> formulation according to claim <u>1</u> 3, wherein the rapamycin comprises is CCI-779.
 - 6. (Cancelled)

- 7. (Cancelled)
- 8. (Cancelled)
- 9. (Cancelled)
- 10. (Cancelled)